KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to 46.15%.

  • Eli Lilly's EBIT Margin rose 67100.0% to 46.15% in Q4 2025 from the same period last year, while for Dec 2025 it was 44.82%, marking a year-over-year increase of 89000.0%. This contributed to the annual value of 44.82% for FY2025, which is 89000.0% up from last year.
  • Latest data reveals that Eli Lilly reported EBIT Margin of 46.15% as of Q4 2025, which was up 67100.0% from 45.57% recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's EBIT Margin registered a high of 46.15% during Q4 2025, and its lowest value of 21.46% during Q2 2021.
  • Its 5-year average for EBIT Margin is 32.62%, with a median of 31.29% in 2021.
  • Per our database at Business Quant, Eli Lilly's EBIT Margin tumbled by -99300bps in 2023 and then skyrocketed by 115000bps in 2025.
  • Quarter analysis of 5 years shows Eli Lilly's EBIT Margin stood at 29.44% in 2021, then decreased by -3bps to 28.44% in 2022, then rose by 13bps to 32.18% in 2023, then rose by 23bps to 39.44% in 2024, then grew by 17bps to 46.15% in 2025.
  • Its EBIT Margin stands at 46.15% for Q4 2025, versus 45.57% for Q3 2025 and 45.13% for Q2 2025.